Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Миома матки и фертильность
Миома матки и фертильность
Кузнецова И.В., Евсюкова Л.В. Миома матки и фертильность. Гинекология. 2016; 18 (3): 23–29.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Несмотря на то что изучению миомы матки (ММ) посвящено множество работ, проблема до настоящего времени остается нерешенной. ММ – наиболее часто встречающееся доброкачественное новообразование половой системы женщины. В последние десятилетия ММ все чаще диагностируется у женщин, планирующих беременность, что связано, в первую очередь, с социальным фактором: современные женщины стремятся отложить время деторождения до достижения стабильного материального и социального статуса, что нередко происходит ближе к позднему репродуктивному возрасту, когда распространенность ММ закономерно повышается. Связь между ММ и нарушением фертильности неоднозначна, но, вне всяких сомнений, наличие ММ следует принимать во внимание у женщин с бесплодием и привычным самопроизвольным выкидышем. Оптимального решения задачи восстановления фертильности у пациенток с ММ не существует, однако сегодня помимо хирургических методов лечения появляется возможность консервативного ведения таких больных. Преимущества и недостатки хирургической и консервативной тактики восстановления фертильности у больных ММ должны подвергнуться оценке и дальнейшей разработке.
Ключевые слова: миома матки, фертильность, бесплодие, привычный самопроизвольный выкидыш, планирование беременности, миомэктомия, улипристала ацетат.
Key words: uterine fibroids, fertility, infertility, recurrent spontaneous miscarriage, pregnancy planning, myomectomy, ulipristal acetate.
Ключевые слова: миома матки, фертильность, бесплодие, привычный самопроизвольный выкидыш, планирование беременности, миомэктомия, улипристала ацетат.
________________________________________________
Key words: uterine fibroids, fertility, infertility, recurrent spontaneous miscarriage, pregnancy planning, myomectomy, ulipristal acetate.
Полный текст
Список литературы
1. Миома матки: диагностика, лечение и реабилитация (клинические рекомендации по ведению больных). Под ред. Л.В.Адамян. М.: 2014. / Mioma matki: diagnostika, lechenie i reabilitatsiia (klinicheskie rekomendatsii po vedeniiu bol'nykh). Pod red. L.V.Adamian. M.: 2014. [in Russian]
2. Marret H, Fritel X, Ouldamer L et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol 2012; 165: 156–64.
3. Parker WH. Etiology, symptomatology and diagnosis of uterine myoma. Fertil Steril 2007; 87: 726–36.
4. Giraudet G, Lucot JP et al. Except fertility, place of myomectomy in perimenopause and after menopause. Gynecol Obstet Biol Reprod 2011; 40 (8): 902–17.
5. Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22: 615–26.
6. Levy BS. Management of uterine fibroids. Acta Obstet Gynecol Scand 2008; 87 (8): 812–23. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008; 90 (Suppl. 5): S125–130.
7. Somigliana E, Vercellini P, Daguati R et al. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007; 13: 465–76.
8. Волков В.Г., Гусева Н.В., Горшкова И.А. Оптимизация консервативного лечения миомы матки антипрогестеронами и оценка влияния проводимой терапии на качество жизни женщин. Вестн. новых мед. технологий. 2011; 18 (1): 92. / Volkov V.G., Guseva N.V., Gorshkova I.A. Optimizatsiia konservativnogo lecheniia miomy matki antiprogesteronami i otsenka vliianiia provodimoi terapii na kachestvo zhizni zhenshchin. Vestn. novykh med. tekhnologii. 2011; 18 (1): 92. [in Russian]
9. Duhan N. Current and emerging treatments for uterine myoma an update. Int J Womens Health 2011; 3: 231–41.
10. Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin NA 2006; 33 (1): 41–58.
11. Chen B, Wen Y, Yu XY, Polan ML. Relaxin increases elastase activity and protease inhibitors in smooth muscle cells from tye myometrium compared with cells from leiomyomas. Fertil Steril 2009; 91 (4): 1351–4.
12. Georgieva B, Milev I, Minkov I et al. Charactrisation of the uterine leiomyoma microRNAome by deep sequencing. Genomics 2012; 99: 275–81.
13. Mäkinen N, Mehine M, Tolvanen J et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252–9.
14. Vegan K. MED12 mutations and uterine fibrinoids. Nature Genetics 2011; 43: 928–31.
15. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an update systematic review of the evidence. Fertil Steril 2009; 91 (4): 1215–23.
16. Indman PD. Hysteroscopic treatment of submucous fibroids. Clin Obstet Gynecol 2006; 49: 811–20.
17. Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act? Obstet Gynecol Clin North Am 2006; 33: 145–52.
18. Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008; 198: 357–66.
19. Chalazonitis A, Tzovara I, Laspas F et al. Hysterosalpingography: technique and applications. Curr Probl Diagn Radiol 2009; 38 (5): 199–205.
20. Dixon D, Parrott EC, Segars JH et al. The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations. Fertil Steril 2006; 86: 800–6.
21. Polena V, Merqui JL, Perrot N et al. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007; 130: 232–7.
22. Di Spezio Sardo A, Mazzon I, Bramante S et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008; 14: 10–9.
23. Петракова С.А., Буянова С.Н., Мгелиашвили М.В. Возможности миомэктомии в коррекции репродуктивного здоровья женщин с миомой матки. Рос. вестн. акушера-гинеколога. 2009; 1: 30–5. / Petrakova S.A., Buianova S.N., Mgeliashvili M.V. Vozmozhnosti miomektomii v korrektsii reproduktivnogo zdorov'ia zhenshchin s miomoi matki. Ros. vestn. akushera-ginekologa. 2009; 1: 30–5. [in Russian]
24. Кулинич С.И., Бурлакова О.А. Предгравидарная подготовка женщин репродуктивного возраста и профилактика рецидива миомы матки в послеоперационном периоде после миомэктомии. Сиб. мед. журн. 2011; 6: 119–22. / Kulinich S.I., Burlakova O.A. Predgravidarnaia podgotovka zhenshchin reproduktivnogo vozrasta i profilaktika retsidiva miomy matki v posleoperatsionnom periode posle miomektomii. Sib. med. zhurn. 2011; 6: 119–22. [in Russian]
25. Meng X, He G, Zhang J. A comparative study of fibroid ablation rates using radio frequency and high-intensity focused ultrasound. Cvir 2010; 33: 794–9.
26. Toor SS, Tan KT, Simons ME. Clinical Failure after Uterine Artery Embolization: Evaluation of Patient and MR Imaging Characteristics. J Vasc Int Radiol 2008; 19: 662–7.
27. Scheurig C, Gauruder-Burmester A, Kluner C. Uterine artery embolization for symptomatic fibroids: short-term versus mid-term changes in disease-specific symptoms, quality of life and magnetic resonance imaging results. Hum Reprod 2006; 21: 3270–7.
28. Smeets AJ, Nijenhuis RJ, Jan van Rooij W. Embolization of Uterine Leiomyomas with Polyzene F-coated Hydrogel Microspheres: Initial Experience. J Vasc Intervent Radiol 2010; 21: 1830–4.
29. Horhoianu IA, Horhoianu VV, Joita D, Carstoiu M, Dorobat B. Uterine artery embolization for leioyomas, ultrasonography and angiography aspects. J Med Life 2012; 5 (4): 491–5.
30. Naguib NNN, Mbalisike E, Nour-Eldin NEA. Leiomyoma Volume Changes at Follow-up after Uterine Artery Embolization: Correlation with the Initial Leiomyoma Volume and Location. J Vasc Intervent Radiol 2010; 21: 490–5.
31. Scheurig-Muenkler C, Koesters C, Grieser C. Treatment failure after uterine artery embolization: Prospective cohort study with multifactorial analysis of possible predictors of long-term outcome. Eur J Radiol 2012; 81: 727–31.
32. Kim HS, Tsai J, Patra A. Effects of Utero-ovarian Anastomoses on Clinical Outcomes and Repeat Intervention Rates after Uterine Artery Embolization. J Vasc Intervent Radiol 2006; 17: 783–9.
33. Smeets AJ, Nijenhuis RJ, Boekkooi PF. Safety and Effectiveness of Uterine Artery Embolization in Patients with Pedunculated Fibroids. J Vasc Intervent Radiol 2009; 20: 1172–5.
34. Firouznia K, Ghanaati H, Sanaati M et al. Pregnancy after uterine artery embolization for symptomatic fibroids: a series of 15 pregnancies. AJR Am J Roentgenol 2009; 192 (6): 1588–92.
35. Mara M, Maskova J, Fucikova Z et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31 (1): 73–85.
36. Hovsepian DM, Ratts VS, Rodriguez M et al. A prospective comparison of the impact of uterine artery embolization, myomectomy, and hysterectomy on ovarian function. J Vasc Interv Radiol 2006; 17 (7): 1111–5.
37. Hehenkamp WJK, Volkers NA, Broekmans FJM et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22 (7): 1996–2005.
38. Yin P, Lin Z, Reierstad S et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010; 70 (4): 1722–30.
39. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2012; 35(2): 223–31.
40. Donnez J, Tomaszewski J, Vázquez F et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366 (5): 421–32.
41. Islam MS, Protic O, Giannubilo SR et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013; 98: 921–34.
42. Spitz AM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obtet Gynecol 2009; 21: 318–24.
43. Maruo T. Translation research in women’s health: From bedside to bench and from bench to bedside. Int J Gynecol Obstet 2010; 109: 83–3.
44. Xu Q, Ohara N, Liu J et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14: 181–91.
45. Yoshida S, Ohara N, Xu Q et al. Cell-type specific actions of progesterone receptor modulators in regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260–73.
46. Donnez J, Tatarchuk TF, Bouchard P et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409–20.
47. Donnez J, Vazquez F, Tomaszewski J et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565–73.
48. Donnez J, Hudecek R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519–27.
49. Mutter GL, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (5): 591–98.
50. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012; 31: 556–69.
51. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92 (9): 3582–9.
52. Luyckx M, Squifflet JL, Jadoul P et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014; 102 (5): 1404–9.
2. Marret H, Fritel X, Ouldamer L et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol 2012; 165: 156–64.
3. Parker WH. Etiology, symptomatology and diagnosis of uterine myoma. Fertil Steril 2007; 87: 726–36.
4. Giraudet G, Lucot JP et al. Except fertility, place of myomectomy in perimenopause and after menopause. Gynecol Obstet Biol Reprod 2011; 40 (8): 902–17.
5. Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22: 615–26.
6. Levy BS. Management of uterine fibroids. Acta Obstet Gynecol Scand 2008; 87 (8): 812–23. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008; 90 (Suppl. 5): S125–130.
7. Somigliana E, Vercellini P, Daguati R et al. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007; 13: 465–76.
8. Volkov V.G., Guseva N.V., Gorshkova I.A. Optimizatsiia konservativnogo lecheniia miomy matki antiprogesteronami i otsenka vliianiia provodimoi terapii na kachestvo zhizni zhenshchin. Vestn. novykh med. tekhnologii. 2011; 18 (1): 92. [in Russian]
9. Duhan N. Current and emerging treatments for uterine myoma an update. Int J Womens Health 2011; 3: 231–41.
10. Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin NA 2006; 33 (1): 41–58.
11. Chen B, Wen Y, Yu XY, Polan ML. Relaxin increases elastase activity and protease inhibitors in smooth muscle cells from tye myometrium compared with cells from leiomyomas. Fertil Steril 2009; 91 (4): 1351–4.
12. Georgieva B, Milev I, Minkov I et al. Charactrisation of the uterine leiomyoma microRNAome by deep sequencing. Genomics 2012; 99: 275–81.
13. Mäkinen N, Mehine M, Tolvanen J et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252–9.
14. Vegan K. MED12 mutations and uterine fibrinoids. Nature Genetics 2011; 43: 928–31.
15. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an update systematic review of the evidence. Fertil Steril 2009; 91 (4): 1215–23.
16. Indman PD. Hysteroscopic treatment of submucous fibroids. Clin Obstet Gynecol 2006; 49: 811–20.
17. Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act? Obstet Gynecol Clin North Am 2006; 33: 145–52.
18. Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008; 198: 357–66.
19. Chalazonitis A, Tzovara I, Laspas F et al. Hysterosalpingography: technique and applications. Curr Probl Diagn Radiol 2009; 38 (5): 199–205.
20. Dixon D, Parrott EC, Segars JH et al. The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations. Fertil Steril 2006; 86: 800–6.
21. Polena V, Merqui JL, Perrot N et al. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007; 130: 232–7.
22. Di Spezio Sardo A, Mazzon I, Bramante S et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008; 14: 10–9.
23. Petrakova S.A., Buianova S.N., Mgeliashvili M.V. Vozmozhnosti miomektomii v korrektsii reproduktivnogo zdorov'ia zhenshchin s miomoi matki. Ros. vestn. akushera-ginekologa. 2009; 1: 30–5. [in Russian]
24. Kulinich S.I., Burlakova O.A. Predgravidarnaia podgotovka zhenshchin reproduktivnogo vozrasta i profilaktika retsidiva miomy matki v posleoperatsionnom periode posle miomektomii. Sib. med. zhurn. 2011; 6: 119–22. [in Russian]
25. Meng X, He G, Zhang J. A comparative study of fibroid ablation rates using radio frequency and high-intensity focused ultrasound. Cvir 2010; 33: 794–9.
26. Toor SS, Tan KT, Simons ME. Clinical Failure after Uterine Artery Embolization: Evaluation of Patient and MR Imaging Characteristics. J Vasc Int Radiol 2008; 19: 662–7.
27. Scheurig C, Gauruder-Burmester A, Kluner C. Uterine artery embolization for symptomatic fibroids: short-term versus mid-term changes in disease-specific symptoms, quality of life and magnetic resonance imaging results. Hum Reprod 2006; 21: 3270–7.
28. Smeets AJ, Nijenhuis RJ, Jan van Rooij W. Embolization of Uterine Leiomyomas with Polyzene F-coated Hydrogel Microspheres: Initial Experience. J Vasc Intervent Radiol 2010; 21: 1830–4.
29. Horhoianu IA, Horhoianu VV, Joita D, Carstoiu M, Dorobat B. Uterine artery embolization for leioyomas, ultrasonography and angiography aspects. J Med Life 2012; 5 (4): 491–5.
30. Naguib NNN, Mbalisike E, Nour-Eldin NEA. Leiomyoma Volume Changes at Follow-up after Uterine Artery Embolization: Correlation with the Initial Leiomyoma Volume and Location. J Vasc Intervent Radiol 2010; 21: 490–5.
31. Scheurig-Muenkler C, Koesters C, Grieser C. Treatment failure after uterine artery embolization: Prospective cohort study with multifactorial analysis of possible predictors of long-term outcome. Eur J Radiol 2012; 81: 727–31.
32. Kim HS, Tsai J, Patra A. Effects of Utero-ovarian Anastomoses on Clinical Outcomes and Repeat Intervention Rates after Uterine Artery Embolization. J Vasc Intervent Radiol 2006; 17: 783–9.
33. Smeets AJ, Nijenhuis RJ, Boekkooi PF. Safety and Effectiveness of Uterine Artery Embolization in Patients with Pedunculated Fibroids. J Vasc Intervent Radiol 2009; 20: 1172–5.
34. Firouznia K, Ghanaati H, Sanaati M et al. Pregnancy after uterine artery embolization for symptomatic fibroids: a series of 15 pregnancies. AJR Am J Roentgenol 2009; 192 (6): 1588–92.
35. Mara M, Maskova J, Fucikova Z et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31 (1): 73–85.
36. Hovsepian DM, Ratts VS, Rodriguez M et al. A prospective comparison of the impact of uterine artery embolization, myomectomy, and hysterectomy on ovarian function. J Vasc Interv Radiol 2006; 17 (7): 1111–5.
37. Hehenkamp WJK, Volkers NA, Broekmans FJM et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22 (7): 1996–2005.
38. Yin P, Lin Z, Reierstad S et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010; 70 (4): 1722–30.
39. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2012; 35(2): 223–31.
40. Donnez J, Tomaszewski J, Vázquez F et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366 (5): 421–32.
41. Islam MS, Protic O, Giannubilo SR et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013; 98: 921–34.
42. Spitz AM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obtet Gynecol 2009; 21: 318–24.
43. Maruo T. Translation research in women’s health: From bedside to bench and from bench to bedside. Int J Gynecol Obstet 2010; 109: 83–3.
44. Xu Q, Ohara N, Liu J et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14: 181–91.
45. Yoshida S, Ohara N, Xu Q et al. Cell-type specific actions of progesterone receptor modulators in regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260–73.
46. Donnez J, Tatarchuk TF, Bouchard P et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409–20.
47. Donnez J, Vazquez F, Tomaszewski J et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565–73.
48. Donnez J, Hudecek R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519–27.
49. Mutter GL, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (5): 591–98.
50. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012; 31: 556–69.
51. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92 (9): 3582–9.
52. Luyckx M, Squifflet JL, Jadoul P et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014; 102 (5): 1404–9.
2. Marret H, Fritel X, Ouldamer L et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol 2012; 165: 156–64.
3. Parker WH. Etiology, symptomatology and diagnosis of uterine myoma. Fertil Steril 2007; 87: 726–36.
4. Giraudet G, Lucot JP et al. Except fertility, place of myomectomy in perimenopause and after menopause. Gynecol Obstet Biol Reprod 2011; 40 (8): 902–17.
5. Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22: 615–26.
6. Levy BS. Management of uterine fibroids. Acta Obstet Gynecol Scand 2008; 87 (8): 812–23. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008; 90 (Suppl. 5): S125–130.
7. Somigliana E, Vercellini P, Daguati R et al. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007; 13: 465–76.
8. Волков В.Г., Гусева Н.В., Горшкова И.А. Оптимизация консервативного лечения миомы матки антипрогестеронами и оценка влияния проводимой терапии на качество жизни женщин. Вестн. новых мед. технологий. 2011; 18 (1): 92. / Volkov V.G., Guseva N.V., Gorshkova I.A. Optimizatsiia konservativnogo lecheniia miomy matki antiprogesteronami i otsenka vliianiia provodimoi terapii na kachestvo zhizni zhenshchin. Vestn. novykh med. tekhnologii. 2011; 18 (1): 92. [in Russian]
9. Duhan N. Current and emerging treatments for uterine myoma an update. Int J Womens Health 2011; 3: 231–41.
10. Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin NA 2006; 33 (1): 41–58.
11. Chen B, Wen Y, Yu XY, Polan ML. Relaxin increases elastase activity and protease inhibitors in smooth muscle cells from tye myometrium compared with cells from leiomyomas. Fertil Steril 2009; 91 (4): 1351–4.
12. Georgieva B, Milev I, Minkov I et al. Charactrisation of the uterine leiomyoma microRNAome by deep sequencing. Genomics 2012; 99: 275–81.
13. Mäkinen N, Mehine M, Tolvanen J et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252–9.
14. Vegan K. MED12 mutations and uterine fibrinoids. Nature Genetics 2011; 43: 928–31.
15. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an update systematic review of the evidence. Fertil Steril 2009; 91 (4): 1215–23.
16. Indman PD. Hysteroscopic treatment of submucous fibroids. Clin Obstet Gynecol 2006; 49: 811–20.
17. Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act? Obstet Gynecol Clin North Am 2006; 33: 145–52.
18. Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008; 198: 357–66.
19. Chalazonitis A, Tzovara I, Laspas F et al. Hysterosalpingography: technique and applications. Curr Probl Diagn Radiol 2009; 38 (5): 199–205.
20. Dixon D, Parrott EC, Segars JH et al. The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations. Fertil Steril 2006; 86: 800–6.
21. Polena V, Merqui JL, Perrot N et al. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007; 130: 232–7.
22. Di Spezio Sardo A, Mazzon I, Bramante S et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008; 14: 10–9.
23. Петракова С.А., Буянова С.Н., Мгелиашвили М.В. Возможности миомэктомии в коррекции репродуктивного здоровья женщин с миомой матки. Рос. вестн. акушера-гинеколога. 2009; 1: 30–5. / Petrakova S.A., Buianova S.N., Mgeliashvili M.V. Vozmozhnosti miomektomii v korrektsii reproduktivnogo zdorov'ia zhenshchin s miomoi matki. Ros. vestn. akushera-ginekologa. 2009; 1: 30–5. [in Russian]
24. Кулинич С.И., Бурлакова О.А. Предгравидарная подготовка женщин репродуктивного возраста и профилактика рецидива миомы матки в послеоперационном периоде после миомэктомии. Сиб. мед. журн. 2011; 6: 119–22. / Kulinich S.I., Burlakova O.A. Predgravidarnaia podgotovka zhenshchin reproduktivnogo vozrasta i profilaktika retsidiva miomy matki v posleoperatsionnom periode posle miomektomii. Sib. med. zhurn. 2011; 6: 119–22. [in Russian]
25. Meng X, He G, Zhang J. A comparative study of fibroid ablation rates using radio frequency and high-intensity focused ultrasound. Cvir 2010; 33: 794–9.
26. Toor SS, Tan KT, Simons ME. Clinical Failure after Uterine Artery Embolization: Evaluation of Patient and MR Imaging Characteristics. J Vasc Int Radiol 2008; 19: 662–7.
27. Scheurig C, Gauruder-Burmester A, Kluner C. Uterine artery embolization for symptomatic fibroids: short-term versus mid-term changes in disease-specific symptoms, quality of life and magnetic resonance imaging results. Hum Reprod 2006; 21: 3270–7.
28. Smeets AJ, Nijenhuis RJ, Jan van Rooij W. Embolization of Uterine Leiomyomas with Polyzene F-coated Hydrogel Microspheres: Initial Experience. J Vasc Intervent Radiol 2010; 21: 1830–4.
29. Horhoianu IA, Horhoianu VV, Joita D, Carstoiu M, Dorobat B. Uterine artery embolization for leioyomas, ultrasonography and angiography aspects. J Med Life 2012; 5 (4): 491–5.
30. Naguib NNN, Mbalisike E, Nour-Eldin NEA. Leiomyoma Volume Changes at Follow-up after Uterine Artery Embolization: Correlation with the Initial Leiomyoma Volume and Location. J Vasc Intervent Radiol 2010; 21: 490–5.
31. Scheurig-Muenkler C, Koesters C, Grieser C. Treatment failure after uterine artery embolization: Prospective cohort study with multifactorial analysis of possible predictors of long-term outcome. Eur J Radiol 2012; 81: 727–31.
32. Kim HS, Tsai J, Patra A. Effects of Utero-ovarian Anastomoses on Clinical Outcomes and Repeat Intervention Rates after Uterine Artery Embolization. J Vasc Intervent Radiol 2006; 17: 783–9.
33. Smeets AJ, Nijenhuis RJ, Boekkooi PF. Safety and Effectiveness of Uterine Artery Embolization in Patients with Pedunculated Fibroids. J Vasc Intervent Radiol 2009; 20: 1172–5.
34. Firouznia K, Ghanaati H, Sanaati M et al. Pregnancy after uterine artery embolization for symptomatic fibroids: a series of 15 pregnancies. AJR Am J Roentgenol 2009; 192 (6): 1588–92.
35. Mara M, Maskova J, Fucikova Z et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31 (1): 73–85.
36. Hovsepian DM, Ratts VS, Rodriguez M et al. A prospective comparison of the impact of uterine artery embolization, myomectomy, and hysterectomy on ovarian function. J Vasc Interv Radiol 2006; 17 (7): 1111–5.
37. Hehenkamp WJK, Volkers NA, Broekmans FJM et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22 (7): 1996–2005.
38. Yin P, Lin Z, Reierstad S et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010; 70 (4): 1722–30.
39. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2012; 35(2): 223–31.
40. Donnez J, Tomaszewski J, Vázquez F et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366 (5): 421–32.
41. Islam MS, Protic O, Giannubilo SR et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013; 98: 921–34.
42. Spitz AM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obtet Gynecol 2009; 21: 318–24.
43. Maruo T. Translation research in women’s health: From bedside to bench and from bench to bedside. Int J Gynecol Obstet 2010; 109: 83–3.
44. Xu Q, Ohara N, Liu J et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14: 181–91.
45. Yoshida S, Ohara N, Xu Q et al. Cell-type specific actions of progesterone receptor modulators in regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260–73.
46. Donnez J, Tatarchuk TF, Bouchard P et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409–20.
47. Donnez J, Vazquez F, Tomaszewski J et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565–73.
48. Donnez J, Hudecek R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519–27.
49. Mutter GL, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (5): 591–98.
50. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012; 31: 556–69.
51. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92 (9): 3582–9.
52. Luyckx M, Squifflet JL, Jadoul P et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014; 102 (5): 1404–9.
________________________________________________
2. Marret H, Fritel X, Ouldamer L et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol 2012; 165: 156–64.
3. Parker WH. Etiology, symptomatology and diagnosis of uterine myoma. Fertil Steril 2007; 87: 726–36.
4. Giraudet G, Lucot JP et al. Except fertility, place of myomectomy in perimenopause and after menopause. Gynecol Obstet Biol Reprod 2011; 40 (8): 902–17.
5. Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22: 615–26.
6. Levy BS. Management of uterine fibroids. Acta Obstet Gynecol Scand 2008; 87 (8): 812–23. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008; 90 (Suppl. 5): S125–130.
7. Somigliana E, Vercellini P, Daguati R et al. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007; 13: 465–76.
8. Volkov V.G., Guseva N.V., Gorshkova I.A. Optimizatsiia konservativnogo lecheniia miomy matki antiprogesteronami i otsenka vliianiia provodimoi terapii na kachestvo zhizni zhenshchin. Vestn. novykh med. tekhnologii. 2011; 18 (1): 92. [in Russian]
9. Duhan N. Current and emerging treatments for uterine myoma an update. Int J Womens Health 2011; 3: 231–41.
10. Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin NA 2006; 33 (1): 41–58.
11. Chen B, Wen Y, Yu XY, Polan ML. Relaxin increases elastase activity and protease inhibitors in smooth muscle cells from tye myometrium compared with cells from leiomyomas. Fertil Steril 2009; 91 (4): 1351–4.
12. Georgieva B, Milev I, Minkov I et al. Charactrisation of the uterine leiomyoma microRNAome by deep sequencing. Genomics 2012; 99: 275–81.
13. Mäkinen N, Mehine M, Tolvanen J et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252–9.
14. Vegan K. MED12 mutations and uterine fibrinoids. Nature Genetics 2011; 43: 928–31.
15. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an update systematic review of the evidence. Fertil Steril 2009; 91 (4): 1215–23.
16. Indman PD. Hysteroscopic treatment of submucous fibroids. Clin Obstet Gynecol 2006; 49: 811–20.
17. Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act? Obstet Gynecol Clin North Am 2006; 33: 145–52.
18. Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008; 198: 357–66.
19. Chalazonitis A, Tzovara I, Laspas F et al. Hysterosalpingography: technique and applications. Curr Probl Diagn Radiol 2009; 38 (5): 199–205.
20. Dixon D, Parrott EC, Segars JH et al. The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations. Fertil Steril 2006; 86: 800–6.
21. Polena V, Merqui JL, Perrot N et al. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007; 130: 232–7.
22. Di Spezio Sardo A, Mazzon I, Bramante S et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008; 14: 10–9.
23. Petrakova S.A., Buianova S.N., Mgeliashvili M.V. Vozmozhnosti miomektomii v korrektsii reproduktivnogo zdorov'ia zhenshchin s miomoi matki. Ros. vestn. akushera-ginekologa. 2009; 1: 30–5. [in Russian]
24. Kulinich S.I., Burlakova O.A. Predgravidarnaia podgotovka zhenshchin reproduktivnogo vozrasta i profilaktika retsidiva miomy matki v posleoperatsionnom periode posle miomektomii. Sib. med. zhurn. 2011; 6: 119–22. [in Russian]
25. Meng X, He G, Zhang J. A comparative study of fibroid ablation rates using radio frequency and high-intensity focused ultrasound. Cvir 2010; 33: 794–9.
26. Toor SS, Tan KT, Simons ME. Clinical Failure after Uterine Artery Embolization: Evaluation of Patient and MR Imaging Characteristics. J Vasc Int Radiol 2008; 19: 662–7.
27. Scheurig C, Gauruder-Burmester A, Kluner C. Uterine artery embolization for symptomatic fibroids: short-term versus mid-term changes in disease-specific symptoms, quality of life and magnetic resonance imaging results. Hum Reprod 2006; 21: 3270–7.
28. Smeets AJ, Nijenhuis RJ, Jan van Rooij W. Embolization of Uterine Leiomyomas with Polyzene F-coated Hydrogel Microspheres: Initial Experience. J Vasc Intervent Radiol 2010; 21: 1830–4.
29. Horhoianu IA, Horhoianu VV, Joita D, Carstoiu M, Dorobat B. Uterine artery embolization for leioyomas, ultrasonography and angiography aspects. J Med Life 2012; 5 (4): 491–5.
30. Naguib NNN, Mbalisike E, Nour-Eldin NEA. Leiomyoma Volume Changes at Follow-up after Uterine Artery Embolization: Correlation with the Initial Leiomyoma Volume and Location. J Vasc Intervent Radiol 2010; 21: 490–5.
31. Scheurig-Muenkler C, Koesters C, Grieser C. Treatment failure after uterine artery embolization: Prospective cohort study with multifactorial analysis of possible predictors of long-term outcome. Eur J Radiol 2012; 81: 727–31.
32. Kim HS, Tsai J, Patra A. Effects of Utero-ovarian Anastomoses on Clinical Outcomes and Repeat Intervention Rates after Uterine Artery Embolization. J Vasc Intervent Radiol 2006; 17: 783–9.
33. Smeets AJ, Nijenhuis RJ, Boekkooi PF. Safety and Effectiveness of Uterine Artery Embolization in Patients with Pedunculated Fibroids. J Vasc Intervent Radiol 2009; 20: 1172–5.
34. Firouznia K, Ghanaati H, Sanaati M et al. Pregnancy after uterine artery embolization for symptomatic fibroids: a series of 15 pregnancies. AJR Am J Roentgenol 2009; 192 (6): 1588–92.
35. Mara M, Maskova J, Fucikova Z et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31 (1): 73–85.
36. Hovsepian DM, Ratts VS, Rodriguez M et al. A prospective comparison of the impact of uterine artery embolization, myomectomy, and hysterectomy on ovarian function. J Vasc Interv Radiol 2006; 17 (7): 1111–5.
37. Hehenkamp WJK, Volkers NA, Broekmans FJM et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22 (7): 1996–2005.
38. Yin P, Lin Z, Reierstad S et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010; 70 (4): 1722–30.
39. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2012; 35(2): 223–31.
40. Donnez J, Tomaszewski J, Vázquez F et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366 (5): 421–32.
41. Islam MS, Protic O, Giannubilo SR et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013; 98: 921–34.
42. Spitz AM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obtet Gynecol 2009; 21: 318–24.
43. Maruo T. Translation research in women’s health: From bedside to bench and from bench to bedside. Int J Gynecol Obstet 2010; 109: 83–3.
44. Xu Q, Ohara N, Liu J et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14: 181–91.
45. Yoshida S, Ohara N, Xu Q et al. Cell-type specific actions of progesterone receptor modulators in regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260–73.
46. Donnez J, Tatarchuk TF, Bouchard P et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409–20.
47. Donnez J, Vazquez F, Tomaszewski J et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565–73.
48. Donnez J, Hudecek R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519–27.
49. Mutter GL, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (5): 591–98.
50. Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012; 31: 556–69.
51. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92 (9): 3582–9.
52. Luyckx M, Squifflet JL, Jadoul P et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014; 102 (5): 1404–9.
Авторы
И.В.Кузнецова*1, Л.В.Евсюкова2
1. ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. ГБОУ ВПО Рязанский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 390026, Россия, Рязань, ул. Высоковольтная, д. 9
*ms.smith.ivk@gmail.com
1. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2. I.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation. 390026, Russian Federation, Ryazan, ul. Vysokovol'tnaia, d. 9
*ms.smith.ivk@gmail.com
1. ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. ГБОУ ВПО Рязанский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 390026, Россия, Рязань, ул. Высоковольтная, д. 9
*ms.smith.ivk@gmail.com
________________________________________________
1. I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2. I.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation. 390026, Russian Federation, Ryazan, ul. Vysokovol'tnaia, d. 9
*ms.smith.ivk@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.